Please note: This is a Sole Source Notification. The Department of Regenerative Medicine and Cell Biology has obtained funding from NIH (DK136328) to examine the mechanism through which our compounds control the production of LDL-C by the liver. This includes determining the mechanism through which the compound inhibits the target enzyme which is called CES1. This goal requires the Department to understand how the compound interacts with the structure of CES1 to block enzymatic activity. Initially they sub-contracted with another University as academic collaborators who were provided with an annual total budget of $114,621. Unfortunately, after two years of support, the Department’s collaborator was unable to generate the crystals necessary to solve the structure and they mutually agreed to discontinue the collaboration.
